LOGO.png
Nemaura Medical to Present at the LD Micro Main Event Conference
05 oct. 2021 08h00 HE | Nemaura Medical, Inc
Loughborough, England, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic...
LOGO.png
Nemaura Medical Launches Beta Version of Its Metabolic Health Program
29 sept. 2021 08h30 HE | Nemaura Medical, Inc
MiBoKo, a noninvasive glucose sensor utilizing AI mobile application, addresses a substantial multibillion-dollar market opportunity in healthcare LOUGHBOROUGH, England, Sept. 29, 2021 (GLOBE...
LOGO.png
Nemaura Medical Announces Commercial Agreement with UK Licensee
27 sept. 2021 08h00 HE | Nemaura Medical, Inc
Nemaura has previously placed order for 200,000 CGMs in anticipation of commercial ramp-up Loughborough, England, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura”...
LOGO.png
Nemaura Medical announce Professor Osama Hamdy Joins their Advisory Board
17 sept. 2021 09h05 HE | Nemaura Medical, Inc
Loughborough, England, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...
LOGO.png
Nemaura Medical Reports Financial Results and Provides Business Update for the First Fiscal Quarter Ended June 30, 2021
16 août 2021 08h30 HE | Nemaura Medical, Inc
Loughborough, England, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...
LOGO.png
Nemaura Medical Announces Presentation on its Licensed Why WAIT Program During the American Diabetes Association 81st Annual Scientific Sessions
30 juin 2021 09h15 HE | Nemaura Medical, Inc
Loughborough, England, June 30, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...